CD38
CD38 Molecule Information
Name：Lymphocyte differentiation antigen CD38
Target Synonym：2 -phospho-ADP-ribosyl cyclase?T10?CD38?2 -phospho-cyclic-ADP-ribose transferase?CD_antigen=CD38?2 -phospho-ADP-ribosyl cyclase/2 -phospho-cyclic-ADP-ribose transferase?ADPRC 1?Cyclic ADP-ribose hydrolase 1?ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase
Number of Launched Drugs：1
Number of Drugs in Clinical Trials：10
Lastest Research Phase：Approved
| Cat. No. |
Species |
Product Description |
Structure |
Purity |
Feature |
| CD8-M5223 |
Mouse |
Mouse CD38 Protein, His Tag |
|
|
|
| CD8-C5223 |
Cynomolgus |
Cynomolgus CD38 Protein, His Tag |
|
|
|
| CD8-H5252 |
Human |
Human CD38 Protein, Llama IgG2b Fc Tag, low endotoxin |
|
|
|
| CD8-H5253 |
Human |
Human CD38 Protein, Mouse IgG2a Fc Tag, low endotoxin |
|
|
|
| CD8-H5255 |
Human |
Human CD38 Protein, Fc Tag |
|
|
|
| CD8-H82E7 |
Human |
Biotinylated Human CD38 Protein, Avitag™,His Tag |
|
|
|
| CD8-H5224 |
Human |
Human CD38 Protein, His Tag |
|
|
|
CD38 Molecule Synonym Name
CD38,T10,cADPr hydrolase 1
CD38 Molecule Background
CD antigen CD38 is also known as ADP-ribosyl cyclase 1, which belongs to the ADP-ribosyl cyclase family. CD38 is expressed at high levels in pancreas, liver, kidney, brain, testis, ovary, placenta, malignant lymphoma and neuroblastoma. CD38 is a multifunctional ectoenzyme that catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD+ to ADP-ribose. These reaction products are essential for the regulation of intracellular Ca2+. The loss of CD38 function is associated with impaired immune responses, metabolic disturbances, and behavioral modifications. The CD38 protein is a marker of cell activation. It has been connected to HIV infection, leukemias, myelomas, solid tumors, type II diabetes mellitus and bone metabolism. CD38 has been used as a prognostic marker in leukemia.
CD38 References
CD38 Public Drug Information
| Name |
Research Code |
Research Phase |
Company |
First Brand Name |
First Approved Country |
First Indication |
First Approved Company |
First Approved Date |
Indications |
Clinical Trials |
| Daratumumab |
3003-005; HuMax-CD38; JNJ-54767414; Dara-SC ,HuMaxCD38 |
Approved |
Janssen |
DARZALEX |
fda |
Multiple myeloma (MM) |
JANSSEN BIOTECH |
2015-11-16 |
Multiple myeloma (MM) |
Details
|
CD38 Clinical Drug Information
| Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
| GBR-1342 |
GBR-1342 |
Phase Ⅰ |
Glenmark Pharma |
Multiple myeloma (MM) |
Details
|
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) |
|
Phase Ⅰ |
Wuhan Union Hospital, Shengyan Pharmaceutical Technology |
Multiple myeloma (MM) |
Details
|
| TAK-079 |
TAK-079,TAK079 |
Phase Ⅱ |
Takeda |
Multiple myeloma (MM) |
Details
|
| AMG-424 |
AMG-424 |
Phase Ⅰ |
Xencor, Amgen |
Multiple myeloma (MM) |
Details
|
| Isatuximab |
SAR-650984,SAR650984 |
BLA Filing |
ImmunoGen, Sanofi |
Multiple myeloma (MM) |
Details
|
| TAK-573 |
TAK-573; TEV-48573 |
Phase Ⅱ |
Takeda |
Multiple myeloma (MM) |
Details
|
| TAK-169 |
TAK-169 |
IND Filing |
Molecular Templates, Takeda |
Multiple myeloma (MM) |
Details
|
| FT-500 |
FT-500; FT-516; FT-538; FT-596 |
Phase Ⅰ |
Fate therapeutics, University of Minnesota |
Solid tumours |
Details
|
| Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) |
|
Phase Ⅰ |
Sorrento Therapeutics, Celularity |
Multiple myeloma (MM) |
Details
|
| MOR-202 |
MOR-202; MOR-03087; TJ-202 |
Phase Ⅲ |
MorphoSys, I-MAB Biopharma |
Multiple myeloma (MM) |
Details
|
A-Z
